| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ANAB Stock Overview
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.15 |
| 52 Week High | US$37.89 |
| 52 Week Low | US$18.20 |
| Beta | 0.15 |
| 1 Month Change | 13.93% |
| 3 Month Change | 8.48% |
| 1 Year Change | -0.43% |
| 3 Year Change | -52.75% |
| 5 Year Change | 11.94% |
| Change since IPO | 36.18% |
Recent News & Updates
AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
AnaptysBio press release (NASDAQ:ANAB): Q2 GAAP EPS of -$1.15 misses by $0.14. Revenue of $1.21M (-96.0% Y/Y) misses by $4.4M.
Shareholder Returns
| ANAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.5% | 6.3% | 0.3% |
| 1Y | -0.4% | -25.9% | -13.5% |
Return vs Industry: ANAB exceeded the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: ANAB exceeded the US Market which returned -13% over the past year.
Price Volatility
| ANAB volatility | |
|---|---|
| ANAB Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 12.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ANAB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 102 | Dan Faga | https://www.anaptysbio.com |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| ANAB fundamental statistics | |
|---|---|
| Market Cap | US$652.51m |
| Earnings (TTM) | -US$108.01m |
| Revenue (TTM) | US$24.09m |
27.1x
P/S Ratio-6.0x
P/E RatioIs ANAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANAB income statement (TTM) | |
|---|---|
| Revenue | US$24.09m |
| Cost of Revenue | US$98.50m |
| Gross Profit | -US$74.41m |
| Other Expenses | US$33.60m |
| Earnings | -US$108.01m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.83 |
| Gross Margin | -308.92% |
| Net Profit Margin | -448.43% |
| Debt/Equity Ratio | 0% |
How did ANAB perform over the long term?
See historical performance and comparison